Management of type 2 diabetes mellitus in chronic kidney disease

Chronic kidney disease (CKD) is a common complication of type 2 diabetes mellitus, with the latter being the main cause of end stage renal disease, which often requires renal replacement therapy1,2...

[1]  V. Mohan,et al.  Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis , 2015, Current medical research and opinion.

[2]  N. Marx,et al.  Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. , 2014, Clinical therapeutics.

[3]  G. Derosa,et al.  Hypoglycemia, its implications in clinical practice, and possible ways to prevent it , 2014, Current medical research and opinion.

[4]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[5]  Patrícia Aires Neto,et al.  Management of hyperglycemia in patients with chronic kidney disease. , 2013, Journal of nephrology.

[6]  S. Prato,et al.  Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin , 2013, Diabetes, metabolic syndrome and obesity : targets and therapy.

[7]  J. McGill,et al.  Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment , 2013, Diabetes Care.

[8]  A. Reutens.  Epidemiology of diabetic kidney disease. , 2013, The Medical clinics of North America.

[9]  Mark E. Williams,et al.  Diabetes management in the kidney patient. , 2013, The Medical clinics of North America.

[10]  R. Bilous,et al.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  G. Derosa,et al.  GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. , 2012, Current Clinical Pharmacology.

[12]  G. Derosa,et al.  Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. , 2012, Current molecular pharmacology.

[13]  G. Derosa,et al.  Dipeptidyl peptidase-4 inhibitors: 3 years of experience. , 2012, Diabetes technology & therapeutics.

[14]  M. Banerji,et al.  Chronic kidney disease and diabetes. , 2012, Maturitas.

[15]  G. Derosa.  Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus , 2010, Drugs.

[16]  M. Soma,et al.  Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. , 2011, Current drug metabolism.

[17]  G. Nahler.  summary of product characteristics (SPC, SmPC) , 2009 .

[18]  R. Perfetti,et al.  Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. , 2003, Endocrinology.

[19]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[20]  J. Egan,et al.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. , 2000, Endocrinology.

[21]  A. Alvestrand.  Carbohydrate and insulin metabolism in renal failure. , 1997, Kidney international. Supplement.

[22]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[23]  P. Waller,et al.  A placebo-controlled, double-blind study of eicosapentaenoic acid-rich fish oil in patients with stable angina pectoris. , 1990, Current medical research and opinion.